Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?
Institute for Inflammation Research, Rigshospitalet, Copenhagen, Denmark.
K
K
Bendtzen
Department of Gastroenterology, Herlev Hospital, Herlev, Denmark.
C
0000-0003-3898-4212
C
Steenholdt
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology; D000917:Antibody Formation / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors; D000069285:Infliximab; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069285:Infliximab; D000068879:Adalimumab